Amerikanische Gesellschaft für Hirudotherapie

National Medicines Regulatory Authority

NMRA · Sri Lanka · asia pacific

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Sri Lanka's National Medicines Regulatory Authority — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general medical device framework or indigenous medicine (Ayurveda) pathways as appropriate.

Regulatory Profile

Agency type
national regulator
Region
asia pacific
Country
Sri Lanka
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • National Medicines Regulatory Authority Act (Sri Lanka)
  • Sri Lankan framework for Ayurveda and indigenous medicine as appropriate

Prescriber Requirements

  • Sri Lanka Medical Council–registered physician — order required for any biomedical device application
  • Ayurvedic practitioners registered under the Ayurvedic Medical Council may have separate scope; specific hirudotherapy authorisation not independently verified by ASH

Supply Chain & GMP

NMRA registration as applicable; Sinhala, Tamil, and English-language labelling. Standard cold-chain conditions.

Import/Export Rules

NMRA import licence requirements; Department of Animal Production and Health clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Not covered under public insurance schemes for leech therapy specifically.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. Sri Lanka has a parallel Department of Ayurveda; leech therapy (jalauka avacharana) is part of classical Ayurvedic practice, but its regulatory status as a clinical modality has not been independently mapped by ASH.

Related Jurisdictions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.